{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:18:58Z","timestamp":1791335938160,"version":"4.3.1"},"reference-count":263,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05518-8","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T14:16:27Z","timestamp":1783174587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumor-induced immune escape mechanisms and translational immunotherapeutic strategies"],"prefix":"10.1007","volume":"17","author":[{"given":"Mohammad","family":"Yousefi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8631-071X","authenticated-orcid":false,"given":"Mohammad Reza","family":"Farahpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazila","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Abedian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8642-6795","authenticated-orcid":false,"given":"Behzad","family":"Baradaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"5518_CR1","doi-asserted-by":"crossref","unstructured":"Ji X et al. Epidemiological analysis of global and regional lung cancer mortality: Based on 30-year data analysis of global burden disease database. in Healthcare. 2023. MDPI.","DOI":"10.3390\/healthcare11222920"},{"issue":"2","key":"5518_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1764","volume":"6","author":"A Pulumati","year":"2023","unstructured":"Pulumati A, et al. Technological advancements in cancer diagnostics: improvements and limitations. Cancer reports (Hoboken, NJ). 2023;6(2):e1764.","journal-title":"Cancer reports (Hoboken, N.J.)"},{"issue":"1","key":"5518_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.34172\/ia.2023.06","volume":"3","author":"N Alizadeh","year":"2023","unstructured":"Alizadeh N, et al. The combination of PD-L1 and CTLA-4 suppression significantly decreased the expression levels of cancer stem cell factors in the pancreatic cancer cell line. ImmunoAnalysis. 2023;3(1):6\u20136.","journal-title":"ImmunoAnalysis"},{"key":"5518_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.584367","volume":"10","author":"J Chen","year":"2021","unstructured":"Chen J, et al. Enhancing the efficacy of tumor vaccines based on immune evasion mechanisms. Front Oncol. 2021;10:584367.","journal-title":"Front Oncol"},{"key":"5518_CR5","unstructured":"Osojnik A. Characterising dynamical systems models of tumour-immune interactions. University of Oxford; 2021."},{"issue":"3","key":"5518_CR6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3390\/cancers13030551","volume":"13","author":"B Seliger","year":"2021","unstructured":"Seliger B, Massa C. Immune therapy resistance and immune escape of tumors. Cancers. 2021;13(3):551.","journal-title":"Cancers"},{"issue":"8","key":"5518_CR7","first-page":"833","volume":"7","author":"A Helmin-Basa","year":"2022","unstructured":"Helmin-Basa A, et al. The application of the natural killer cells, macrophages and dendritic cells in treating various types of cancer. Phys Sci Reviews. 2022;7(8):833\u201366.","journal-title":"Phys Sci Reviews"},{"key":"5518_CR8","doi-asserted-by":"publisher","first-page":"e82786","DOI":"10.7554\/eLife.82786","volume":"12","author":"JT George","year":"2023","unstructured":"George JT, Levine H. Optimal cancer evasion in a dynamic immune microenvironment generates diverse post-escape tumor antigenicity profiles. Elife. 2023;12:e82786.","journal-title":"Elife"},{"key":"5518_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2174\/9789815124606123010009","volume-title":"Molecular Targets and Cancer Therapeutics Part II","author":"AF Alshammary","year":"2023","unstructured":"Alshammary AF. Cancer Surveillance. In: Molecular Targets and Cancer Therapeutics Part II. Bentham Science Publishers; 2023. p. 271\u2013341."},{"issue":"6","key":"5518_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061642","volume":"15","author":"K Starska-Kowarska","year":"2023","unstructured":"Starska-Kowarska K. The role of different immunocompetent cell populations in the pathogenesis of head and neck cancer\u2014regulatory mechanisms of pro-and anti-cancer activity and their impact on immunotherapy. Cancers (Basel). 2023;15(6):1642.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"5518_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","volume":"17","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2020;17(1):1\u201312.","journal-title":"Cell Mol Immunol"},{"key":"5518_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1129343","volume":"11","author":"V Bhardwaj","year":"2023","unstructured":"Bhardwaj V, Ansell SM. Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies. Front Cell Dev Biol. 2023;11:1129343.","journal-title":"Front Cell Dev Biol"},{"key":"5518_CR13","doi-asserted-by":"publisher","first-page":"153485","DOI":"10.1016\/j.prp.2021.153485","volume":"223","author":"S Mehdizadeh","year":"2021","unstructured":"Mehdizadeh S, et al. Immune checkpoints and cancer development: Therapeutic implications and future directions. Pathology-Research Pract. 2021;223:153485.","journal-title":"Pathology-Research Pract"},{"issue":"19","key":"5518_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910389","volume":"22","author":"N Hosseinkhani","year":"2021","unstructured":"Hosseinkhani N, et al. A systematic review and meta-analysis on the significance of TIGIT in solid cancers: dual TIGIT\/PD-1 blockade to overcome immune-resistance in solid cancers. Int J Mol Sci. 2021;22(19):10389.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"5518_CR15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2174\/1566524022666220610094716","volume":"23","author":"S Ghahremani Dehbokri","year":"2023","unstructured":"Ghahremani Dehbokri S, et al. CTLA-4: as an immunosuppressive immune checkpoint in breast cancer. Curr Mol Med. 2023;23(6):521\u20136.","journal-title":"Curr Mol Med"},{"issue":"7","key":"5518_CR16","first-page":"459","volume":"14","author":"N Alizadeh","year":"2016","unstructured":"Alizadeh N, et al. Frequency of null allele of Human Leukocyte Antigen-G (HLA-G) locus in subjects to recurrent miscarriage. Int J Reproductive Biomed. 2016;14(7):459.","journal-title":"Int J Reproductive Biomed"},{"issue":"1","key":"5518_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","volume":"15","author":"Y Wang","year":"2022","unstructured":"Wang Y, et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J Hematol Oncol. 2022;15(1):111.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"5518_CR18","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3390\/molecules26082278","volume":"26","author":"A Derakhshani","year":"2021","unstructured":"Derakhshani A, et al. From oncogenic signaling pathways to single-cell sequencing of immune cells: changing the landscape of cancer immunotherapy. Molecules. 2021;26(8):2278.","journal-title":"Molecules"},{"issue":"21","key":"5518_CR19","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non\u2013small-cell lung cancer with PD-L1 tumor proportion score\u2009\u2265\u200950%. J Clin Oncol. 2021;39(21):2339\u201349.","journal-title":"J Clin Oncol"},{"issue":"1","key":"5518_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12964-022-00838-y","volume":"20","author":"MJ Ansari","year":"2022","unstructured":"Ansari MJ, et al. Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. Cell Communication Signal. 2022;20(1):49.","journal-title":"Cell Communication Signal"},{"issue":"21","key":"5518_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216537","volume":"13","author":"P Garg","year":"2024","unstructured":"Garg P, et al. Next-generation immunotherapy: advancing clinical applications in cancer treatment. J Clin Med. 2024;13(21):6537.","journal-title":"J Clin Med"},{"issue":"9","key":"5518_CR22","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1002\/eji.201545552","volume":"45","author":"C Bonini","year":"2015","unstructured":"Bonini C, Mondino A. Adoptive T-cell therapy for cancer: the era of engineered T cells. Eur J Immunol. 2015;45(9):2457\u201369.","journal-title":"Eur J Immunol"},{"issue":"3","key":"5518_CR23","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/cells11030410","volume":"11","author":"F F\u00fcchsl","year":"2022","unstructured":"F\u00fcchsl F, Krackhardt AM. Adoptive cellular therapy for multiple myeloma using CAR-and TCR-transgenic T cells: response and resistance. Cells. 2022;11(3):410.","journal-title":"Cells"},{"issue":"6","key":"5518_CR24","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.3390\/cells9061485","volume":"9","author":"JA Rath","year":"2020","unstructured":"Rath JA, Arber C. Engineering strategies to enhance TCR-based adoptive T cell therapy. Cells. 2020;9(6):1485.","journal-title":"Cells"},{"issue":"1","key":"5518_CR25","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan T, et al. Therapeutic cancer vaccines: advancements, challenges and prospects. Signal Transduct Target Therapy. 2023;8(1):450.","journal-title":"Signal Transduct Target Therapy"},{"issue":"2","key":"5518_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","volume":"9","author":"R Ma","year":"2023","unstructured":"Ma R, et al. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2023;9(2):122\u201339.","journal-title":"Trends Cancer"},{"issue":"1","key":"5518_CR27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","volume":"8","author":"T Zhao","year":"2023","unstructured":"Zhao T, et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct Target therapy. 2023;8(1):283.","journal-title":"Signal Transduct Target therapy"},{"issue":"9","key":"5518_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092241","volume":"14","author":"N Huyghe","year":"2022","unstructured":"Huyghe N, et al. Biomarkers of response and resistance to immunotherapy in microsatellite stable colorectal cancer: toward a new personalized medicine. Cancers. 2022;14(9):2241.","journal-title":"Cancers"},{"key":"5518_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.641469","volume":"9","author":"P Wu","year":"2021","unstructured":"Wu P, et al. Adaptive mechanisms of tumor therapy resistance driven by tumor microenvironment. Front Cell Dev Biol. 2021;9:641469.","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"5518_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023;41(3):421\u201333.","journal-title":"Cancer Cell"},{"key":"5518_CR31","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-981-15-3266-5_9","volume-title":"Regulation of cancer immune checkpoints: molecular and cellular mechanisms and therapy","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zheng J. Functions of immune checkpoint molecules beyond immune evasion. In: Regulation of cancer immune checkpoints: molecular and cellular mechanisms and therapy. 2020. p. 201\u201326."},{"key":"5518_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:1\u201314.","journal-title":"Mol Cancer"},{"key":"5518_CR33","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fimmu.2020.00167","volume":"11","author":"M Khan","year":"2020","unstructured":"Khan M, Arooj S, Wang H. NK cell-based immune checkpoint inhibition. Front Immunol. 2020;11:167.","journal-title":"Front Immunol"},{"key":"5518_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.837645","volume":"13","author":"VC Brom","year":"2022","unstructured":"Brom VC, et al. The role of immune checkpoint molecules on macrophages in cancer, infection, and autoimmune pathologies. Front Immunol. 2022;13:837645.","journal-title":"Front Immunol"},{"key":"5518_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.coi.2014.01.002","volume":"27","author":"JL Perez-Gracia","year":"2014","unstructured":"Perez-Gracia JL, et al. Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Curr Opin Immunol. 2014;27:89\u201397.","journal-title":"Curr Opin Immunol"},{"issue":"22","key":"5518_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212330","volume":"22","author":"A Palicelli","year":"2021","unstructured":"Palicelli A, et al. What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. Part 3: PD-L1, intracellular signaling pathways and tumor microenvironment. Int J Mol Sci. 2021;22(22):12330.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"5518_CR37","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","volume":"23","author":"JH Yearley","year":"2017","unstructured":"Yearley JH, et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res. 2017;23(12):3158\u201367.","journal-title":"Clin Cancer Res"},{"key":"5518_CR38","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1245\/s10434-015-4903-7","volume":"23","author":"S-J Shin","year":"2016","unstructured":"Shin S-J, et al. Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins status. Ann Surg Oncol. 2016;23:694\u2013702.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"5518_CR39","doi-asserted-by":"publisher","first-page":"513","DOI":"10.14348\/molcells.2022.2056","volume":"45","author":"G-R Kim","year":"2022","unstructured":"Kim G-R, Choi J-M. Current understanding of cytotoxic T lymphocyte antigen-4 (CTLA-4) signaling in T-cell biology and disease therapy. Mol Cells. 2022;45(8):513\u201321.","journal-title":"Mol Cells"},{"key":"5518_CR40","unstructured":"Waters EA. The role of ligand and receptor dimerisation in control of CD28 and CTLA4 function. 2023, UCL (University College London)."},{"issue":"2","key":"5518_CR41","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity. 2024;57(2):206\u201322.","journal-title":"Immunity"},{"issue":"1","key":"5518_CR42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16(1):101.","journal-title":"J Hematol Oncol"},{"key":"5518_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","volume":"387","author":"T Wu","year":"2017","unstructured":"Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61\u20138.","journal-title":"Cancer Lett"},{"key":"5518_CR44","first-page":"1019","volume-title":"An immune-active tumor microenvironment favors clinical response to ipilimumab","author":"R-R Ji","year":"2012","unstructured":"Ji R-R, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Volume 61. Immunotherapy: Cancer Immunology; 2012. pp. 1019\u201331."},{"issue":"12","key":"5518_CR45","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.3390\/polym12122935","volume":"12","author":"MM Abbass","year":"2020","unstructured":"Abbass MM, et al. Hydrogels and dentin\u2013pulp complex regeneration: from the benchtop to clinical translation. Polymers. 2020;12(12):2935.","journal-title":"Polymers"},{"key":"5518_CR46","doi-asserted-by":"publisher","DOI":"10.1177\/20503121211069012","volume":"10","author":"B Mirlekar","year":"2022","unstructured":"Mirlekar B. Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: its implications in cancer immunotherapy. SAGE Open Med. 2022;10:20503121211069012.","journal-title":"SAGE Open Med"},{"issue":"1","key":"5518_CR47","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","volume":"10","author":"M Tufail","year":"2025","unstructured":"Tufail M, Jiang C-H, Li N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct Target therapy. 2025;10(1):227.","journal-title":"Signal Transduct Target therapy"},{"issue":"1","key":"5518_CR48","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41568-021-00413-6","volume":"22","author":"DV Tauriello","year":"2022","unstructured":"Tauriello DV, Sancho E, Batlle E. Overcoming TGF\u03b2-mediated immune evasion in cancer. Nat Rev Cancer. 2022;22(1):25\u201344.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"5518_CR49","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00262-023-03616-y","volume":"73","author":"Y Huang","year":"2024","unstructured":"Huang Y, et al. The complex role of IL-10 in malignant ascites: a review. Cancer Immunol Immunother. 2024;73(2):32.","journal-title":"Cancer Immunol Immunother"},{"key":"5518_CR50","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/978-3-032-00749-0_25","volume-title":"Cancer Immunology: The Immune System and Tumor","author":"S Tahmasebi","year":"2025","unstructured":"Tahmasebi S. Pro-tumorigenic and anti-tumorigenic roles of pro-inflammatory cytokines in cancer. In: Cancer Immunology: The Immune System and Tumor. Springer; 2025. p. 529\u201353."},{"issue":"2","key":"5518_CR51","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1158\/1535-7163.MCT-23-0242","volume":"23","author":"P Yi","year":"2024","unstructured":"Yi P, et al. IL-35: new target for immunotherapy targeting the tumor microenvironment. Mol Cancer Ther. 2024;23(2):148\u201358.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"5518_CR52","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s40001-024-01711-z","volume":"29","author":"T Abdul-Rahman","year":"2024","unstructured":"Abdul-Rahman T, et al. The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review. Eur J Med Res. 2024;29(1):124.","journal-title":"Eur J Med Res"},{"key":"5518_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1601773","volume":"16","author":"FP Kraja","year":"2025","unstructured":"Kraja FP, et al. Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling. Front Immunol. 2025;16:1601773.","journal-title":"Front Immunol"},{"key":"5518_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1654947","volume":"16","author":"C Zhang","year":"2025","unstructured":"Zhang C, et al. Dual roles of innate immune cells and cytokines in shaping the breast cancer microenvironment. Front Immunol. 2025;16:1654947.","journal-title":"Front Immunol"},{"issue":"11","key":"5518_CR55","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.3390\/biom12111627","volume":"12","author":"K Yu","year":"2022","unstructured":"Yu K, et al. The Function and therapeutic implications of TNF signaling in MDSCs. Biomolecules. 2022;12(11):1627.","journal-title":"Biomolecules"},{"issue":"3","key":"5518_CR56","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/CMR.0000000000000522","volume":"29","author":"S Salmi","year":"2019","unstructured":"Salmi S, et al. The number and localization of CD68\u2009+\u2009and CD163\u2009+\u2009macrophages in different stages of cutaneous melanoma. Melanoma Res. 2019;29(3):237\u201347.","journal-title":"Melanoma Res"},{"key":"5518_CR57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fonc.2018.00003","volume":"8","author":"T Fujimura","year":"2018","unstructured":"Fujimura T, et al. Tumor-associated macrophages: therapeutic targets for skin cancer. Front Oncol. 2018;8:3.","journal-title":"Front Oncol"},{"key":"5518_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-5086-y","volume":"18","author":"L Ai","year":"2018","unstructured":"Ai L, et al. Prognostic role of myeloid-derived suppressor cells in cancers: a systematic review and meta-analysis. BMC Cancer. 2018;18:1\u20139.","journal-title":"BMC Cancer"},{"issue":"1","key":"5518_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/srep15179","volume":"5","author":"B Shang","year":"2015","unstructured":"Shang B, et al. Prognostic value of tumor-infiltrating FoxP3\u2009+\u2009regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5(1):15179.","journal-title":"Sci Rep"},{"issue":"11","key":"5518_CR60","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/nrc2250","volume":"7","author":"MP Colombo","year":"2007","unstructured":"Colombo MP, Piconese S. Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer. 2007;7(11):880\u20137.","journal-title":"Nat Rev Cancer"},{"key":"5518_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03070","volume":"10","author":"C Siret","year":"2020","unstructured":"Siret C, et al. Deciphering the crosstalk between myeloid-derived suppressor cells and regulatory T cells in pancreatic ductal adenocarcinoma. Front Immunol. 2020;10:3070.","journal-title":"Front Immunol"},{"issue":"2","key":"5518_CR62","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.immuni.2023.01.004","volume":"56","author":"S Dikiy","year":"2023","unstructured":"Dikiy S, Rudensky AY. Principles of regulatory T cell function. Immunity. 2023;56(2):240\u201355.","journal-title":"Immunity"},{"key":"5518_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1387975","volume":"15","author":"Y Zong","year":"2024","unstructured":"Zong Y, Deng K, Chong WP. Regulation of Treg cells by cytokine signaling and co-stimulatory molecules. Front Immunol. 2024;15:1387975.","journal-title":"Front Immunol"},{"key":"5518_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1033705","volume":"13","author":"M Abdeladhim","year":"2022","unstructured":"Abdeladhim M, Karnell JL, Rieder SA. In or out of control: modulating regulatory T cell homeostasis and function with immune checkpoint pathways. Front Immunol. 2022;13:1033705.","journal-title":"Front Immunol"},{"key":"5518_CR65","volume-title":"Human Leukocyte Antigens-Updates and Advances: Updates and Advances","author":"S G\u00f6nen","year":"2023","unstructured":"G\u00f6nen S. Human Leukocyte Antigens-Updates and Advances: Updates and Advances. BoD\u2013Books on Demand; 2023."},{"issue":"1","key":"5518_CR66","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1146\/annurev-immunol-101921-045939","volume":"41","author":"W Chen","year":"2023","unstructured":"Chen W. TGF-\u03b2 Regulation of T Cells. Annu Rev Immunol. 2023;41(1):483\u2013512.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"5518_CR67","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4110\/in.2011.11.1.11","volume":"11","author":"T-Y Ha","year":"2011","unstructured":"Ha T-Y. The role of microRNAs in regulatory T cells and in the immune response. Immune Netw. 2011;11(1):11\u201341.","journal-title":"Immune Netw"},{"key":"5518_CR68","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S562593","author":"D Liu","year":"2025","unstructured":"Liu D, et al. Crosstalk between extracellular vesicles and regulatory T cells across cancers: from interaction to therapeutic potential. Int J Nanomedicine. 2025. https:\/\/doi.org\/10.2147\/IJN.S562593.","journal-title":"Int J Nanomedicine"},{"key":"5518_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.982986","volume":"13","author":"Y Qiu","year":"2022","unstructured":"Qiu Y, et al. FOXP3+ regulatory T cells and the immune escape in solid tumours. Front Immunol. 2022;13:982986.","journal-title":"Front Immunol"},{"issue":"7","key":"5518_CR70","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.intimp.2011.03.003","volume":"11","author":"S Ueha","year":"2011","unstructured":"Ueha S, Shand FH, Matsushima K. Myeloid cell population dynamics in healthy and tumor-bearing mice. Int Immunopharmacol. 2011;11(7):783\u20138.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"5518_CR71","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/cytob.21206","volume":"88","author":"V Damuzzo","year":"2015","unstructured":"Damuzzo V, et al. Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry Part B: Clin Cytometry. 2015;88(2):77\u201391.","journal-title":"Cytometry Part B: Clin Cytometry"},{"issue":"1","key":"5518_CR72","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-15-0224","volume":"6","author":"G Wang","year":"2016","unstructured":"Wang G, et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov. 2016;6(1):80\u201395.","journal-title":"Cancer Discov"},{"issue":"2","key":"5518_CR73","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.celrep.2015.06.024","volume":"12","author":"E Chun","year":"2015","unstructured":"Chun E, et al. CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep. 2015;12(2):244\u201357.","journal-title":"Cell Rep"},{"key":"5518_CR74","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11060-015-1720-6","volume":"122","author":"B Raychaudhuri","year":"2015","unstructured":"Raychaudhuri B, et al. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. J Neurooncol. 2015;122:293\u2013301.","journal-title":"J Neurooncol"},{"issue":"5","key":"5518_CR75","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/ijc.26123","volume":"130","author":"E Eruslanov","year":"2012","unstructured":"Eruslanov E, et al. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer. 2012;130(5):1109\u201319.","journal-title":"Int J Cancer"},{"key":"5518_CR76","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00262-011-1178-0","volume":"61","author":"MR Porembka","year":"2012","unstructured":"Porembka MR, et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother. 2012;61:1373\u201385.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"5518_CR77","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.4049\/jimmunol.1201449","volume":"190","author":"J Yu","year":"2013","unstructured":"Yu J, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190(7):3783\u201397.","journal-title":"J Immunol"},{"issue":"7","key":"5518_CR78","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1084\/jem.20141836","volume":"212","author":"T Kitamura","year":"2015","unstructured":"Kitamura T, et al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J Exp Med. 2015;212(7):1043\u201359.","journal-title":"J Exp Med"},{"issue":"8","key":"5518_CR79","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood-2004-03-1109","volume":"104","author":"C Murdoch","year":"2004","unstructured":"Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood. 2004;104(8):2224\u201334.","journal-title":"Blood"},{"issue":"7355","key":"5518_CR80","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature10138","volume":"475","author":"B-Z Qian","year":"2011","unstructured":"Qian B-Z, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222\u20135.","journal-title":"Nature"},{"issue":"7","key":"5518_CR81","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1609","volume":"13","author":"S Nagaraj","year":"2007","unstructured":"Nagaraj S, et al. Altered recognition of antigen is a mechanism of CD8\u2009+\u2009T cell tolerance in cancer. Nat Med. 2007;13(7):828\u201335.","journal-title":"Nat Med"},{"issue":"12","key":"5518_CR82","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1002\/ijc.28622","volume":"134","author":"PL Raber","year":"2014","unstructured":"Raber PL, et al. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide\u2010related pathways. Int J Cancer. 2014;134(12):2853\u201364.","journal-title":"Int J Cancer"},{"issue":"10","key":"5518_CR83","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1084\/jem.20101956","volume":"208","author":"B Molon","year":"2011","unstructured":"Molon B, et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med. 2011;208(10):1949\u201362.","journal-title":"J Exp Med"},{"issue":"6\u20137","key":"5518_CR84","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3109\/08820139.2012.680634","volume":"41","author":"P Raber","year":"2012","unstructured":"Raber P, Ochoa AC, Rodr\u00edguez PC. Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest. 2012;41(6\u20137):614\u201334.","journal-title":"Immunol Invest"},{"issue":"1","key":"5518_CR85","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/0008-5472.CAN-09-2587","volume":"70","author":"MK Srivastava","year":"2010","unstructured":"Srivastava MK, et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010;70(1):68\u201377.","journal-title":"Cancer Res"},{"issue":"8","key":"5518_CR86","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.4049\/jimmunol.0802740","volume":"182","author":"S Ostrand-Rosenberg","year":"2009","unstructured":"Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182(8):4499\u2013506.","journal-title":"J Immunol"},{"issue":"1","key":"5518_CR87","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/0008-5472.CAN-09-1882","volume":"70","author":"P-Y Pan","year":"2010","unstructured":"Pan P-Y, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 2010;70(1):99\u2013108.","journal-title":"Cancer Res"},{"issue":"15","key":"5518_CR88","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1158\/1078-0432.CCR-14-0635","volume":"20","author":"Y Mao","year":"2014","unstructured":"Mao Y, et al. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin Cancer Res. 2014;20(15):4096\u2013106.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"5518_CR89","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253\u201368.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"5518_CR90","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/ni.2526","volume":"14","author":"J-I Youn","year":"2013","unstructured":"Youn J-I, et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol. 2013;14(3):211\u201320.","journal-title":"Nat Immunol"},{"key":"5518_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-014-1639-3","volume":"64","author":"MN Messmer","year":"2015","unstructured":"Messmer MN, et al. Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol Immunother. 2015;64:1\u201313.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"5518_CR92","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/nyas.12469","volume":"1319","author":"S Solito","year":"2014","unstructured":"Solito S, et al. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci. 2014;1319(1):47\u201365.","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"5518_CR93","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.4049\/jimmunol.0902661","volume":"184","author":"S Nagaraj","year":"2010","unstructured":"Nagaraj S, et al. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol. 2010;184(6):3106\u201316.","journal-title":"J Immunol"},{"key":"5518_CR94","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2119\/molmed.2010.00178","volume":"17","author":"AG Cuenca","year":"2011","unstructured":"Cuenca AG, et al. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol Med. 2011;17:281\u201392.","journal-title":"Mol Med"},{"issue":"1","key":"5518_CR95","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/eji.200939903","volume":"40","author":"L Dolcetti","year":"2010","unstructured":"Dolcetti L, et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM\u2010CSF. Eur J Immunol. 2010;40(1):22\u201335.","journal-title":"Eur J Immunol"},{"issue":"6","key":"5518_CR96","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.immuni.2014.10.020","volume":"41","author":"JM Haverkamp","year":"2014","unstructured":"Haverkamp JM, et al. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity. 2014;41(6):947\u201359.","journal-title":"Immunity"},{"issue":"5","key":"5518_CR97","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, et al. PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781\u201390.","journal-title":"J Exp Med"},{"issue":"6","key":"5518_CR98","doi-asserted-by":"publisher","first-page":"e1008371","DOI":"10.1080\/2162402X.2015.1008371","volume":"4","author":"K Ridder","year":"2015","unstructured":"Ridder K, et al. Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. Oncoimmunology. 2015;4(6):e1008371.","journal-title":"Oncoimmunology"},{"key":"5518_CR99","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00432-009-0634-0","volume":"136","author":"C-Y Liu","year":"2010","unstructured":"Liu C-Y, et al. Population alterations of L-arginase-and inducible nitric oxide synthase-expressed CD11b+\/CD14\u2013\/CD15+\/CD33\u2009+\u2009myeloid-derived suppressor cells and CD8\u2009+\u2009T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;136:35\u201345.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"5518_CR100","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/547179","volume":"2010","author":"P Allavena","year":"2010","unstructured":"Allavena P, et al. Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. J Immunol Res. 2010;2010(1):547179.","journal-title":"J Immunol Res"},{"key":"5518_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2014.12.045","volume":"1619","author":"JC Gensel","year":"2015","unstructured":"Gensel JC, Zhang B. Macrophage activation and its role in repair and pathology after spinal cord injury. Brain Res. 2015;1619:1\u201311.","journal-title":"Brain Res"},{"issue":"12","key":"5518_CR102","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1111\/cas.12015","volume":"103","author":"Y Komohara","year":"2012","unstructured":"Komohara Y, et al. Importance of direct macrophage-tumor cell interaction on progression of human glioma. Cancer Sci. 2012;103(12):2165\u201372.","journal-title":"Cancer Sci"},{"issue":"7","key":"5518_CR103","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/cas.12167","volume":"104","author":"Y Komohara","year":"2013","unstructured":"Komohara Y, et al. Clinical significance of CD 163\u2009+\u2009tumor-associated macrophages in patients with adult T\u2010cell leukemia\/lymphoma. Cancer Sci. 2013;104(7):945\u201351.","journal-title":"Cancer Sci"},{"issue":"6C","key":"5518_CR104","first-page":"4281","volume":"22","author":"I Hamada","year":"2002","unstructured":"Hamada I, et al. Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res. 2002;22(6\u00a0C):4281\u20134.","journal-title":"Anticancer Res"},{"issue":"3","key":"5518_CR105","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/sj.bjc.6603240","volume":"95","author":"S Zeisberger","year":"2006","unstructured":"Zeisberger S, et al. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer. 2006;95(3):272\u201381.","journal-title":"Br J Cancer"},{"key":"5518_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-9-273","volume":"9","author":"A Rigo","year":"2010","unstructured":"Rigo A, et al. Macrophages may promote cancer growth via a GM-CSF\/HB-EGF paracrine loop that is enhanced by CXCL12. Mol Cancer. 2010;9:1\u201313.","journal-title":"Mol Cancer"},{"issue":"8","key":"5518_CR107","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nm0810-861","volume":"16","author":"C Ruhrberg","year":"2010","unstructured":"Ruhrberg C, De Palma M. A double agent in cancer: deciphering macrophage roles in human tumors. Nat Med. 2010;16(8):861\u20132.","journal-title":"Nat Med"},{"issue":"3","key":"5518_CR108","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1021\/mp1004228","volume":"8","author":"EA Vasievich","year":"2011","unstructured":"Vasievich EA, Huang L. The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm. 2011;8(3):635\u201341.","journal-title":"Mol Pharm"},{"key":"5518_CR109","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/978-94-007-0782-5_7","volume-title":"Cell fusion in Health and disease: II: cell fusion in disease","author":"I Shabo","year":"2011","unstructured":"Shabo I, Svanvik J. Expression of macrophage antigens by tumor cells. In: Cell fusion in Health and disease: II: cell fusion in disease. 2011. p. 141\u201350."},{"issue":"2","key":"5518_CR110","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.niox.2008.04.021","volume":"19","author":"A Weigert","year":"2008","unstructured":"Weigert A, Br\u00fcne B. Nitric oxide, apoptosis and macrophage polarization during tumor progression. Nitric Oxide. 2008;19(2):95\u2013102.","journal-title":"Nitric Oxide"},{"issue":"2","key":"5518_CR111","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.niox.2008.04.026","volume":"19","author":"H Yasuda","year":"2008","unstructured":"Yasuda H. Solid tumor physiology and hypoxia-induced chemo\/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide. 2008;19(2):205\u201316.","journal-title":"Nitric Oxide"},{"issue":"1","key":"5518_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/srep18648","volume":"5","author":"Y Li","year":"2015","unstructured":"Li Y, et al. Functions of miR-146a and miR-222 in tumor-associated macrophages in breast cancer. Sci Rep. 2015;5(1):18648.","journal-title":"Sci Rep"},{"issue":"23","key":"5518_CR113","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1038\/onc.2013.258","volume":"33","author":"J Yang","year":"2014","unstructured":"Yang J, et al. MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene. Oncogene. 2014;33(23):3014\u201323.","journal-title":"Oncogene"},{"issue":"5","key":"5518_CR114","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/jmcb\/mjs044","volume":"4","author":"X Cai","year":"2012","unstructured":"Cai X, et al. Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155. J Mol Cell Biol. 2012;4(5):341\u20133.","journal-title":"J Mol Cell Biol"},{"issue":"12","key":"5518_CR115","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/2326-6066.CIR-17-0479","volume":"6","author":"J Zhou","year":"2018","unstructured":"Zhou J, et al. Exosomes released from tumor-associated macrophages transfer miRNAs that induce a Treg\/Th17 cell imbalance in epithelial ovarian cancer. Cancer Immunol Res. 2018;6(12):1578\u201392.","journal-title":"Cancer Immunol Res"},{"key":"5518_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1095-1","volume":"38","author":"X Zhu","year":"2019","unstructured":"Zhu X, et al. Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype. J Experimental Clin Cancer Res. 2019;38:1\u201314.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"1","key":"5518_CR117","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/0008-5472.CAN-18-0014","volume":"79","author":"J Lan","year":"2019","unstructured":"Lan J, et al. M2 macrophage-derived exosomes promote cell migration and invasion in colon cancer. Cancer Res. 2019;79(1):146\u201358.","journal-title":"Cancer Res"},{"issue":"4","key":"5518_CR118","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41419-018-0465-5","volume":"9","author":"P Zheng","year":"2018","unstructured":"Zheng P, et al. Tumor-associated macrophages-derived exosomes promote the migration of gastric cancer cells by transfer of functional apolipoprotein E. Cell Death Dis. 2018;9(4):434.","journal-title":"Cell Death Dis"},{"issue":"10","key":"5518_CR119","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1016\/j.celrep.2019.05.008","volume":"27","author":"C Cianciaruso","year":"2019","unstructured":"Cianciaruso C, et al. Molecular profiling and functional analysis of macrophage-derived tumor extracellular vesicles. Cell Rep. 2019;27(10):3062-3080. e11.","journal-title":"Cell Rep"},{"issue":"3","key":"5518_CR120","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174\u201386.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"5518_CR121","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s43018-022-00411-z","volume":"3","author":"D Lavie","year":"2022","unstructured":"Lavie D, et al. Cancer-associated fibroblasts in the single-cell era. Nat cancer. 2022;3(7):793\u2013807.","journal-title":"Nat cancer"},{"issue":"12","key":"5518_CR122","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","volume":"18","author":"Y Chen","year":"2021","unstructured":"Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18(12):792\u2013804.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"5518_CR123","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582\u201398.","journal-title":"Nat Rev Cancer"},{"key":"5518_CR124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20:1\u201330.","journal-title":"Mol Cancer"},{"issue":"6","key":"5518_CR125","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ccell.2021.03.012","volume":"39","author":"S Affo","year":"2021","unstructured":"Affo S, et al. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell. 2021;39(6):866-882.e11.","journal-title":"Cancer Cell"},{"key":"5518_CR126","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10456-019-09688-8","volume":"23","author":"D Unterleuthner","year":"2020","unstructured":"Unterleuthner D, et al. Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer. Angiogenesis. 2020;23:159\u201377.","journal-title":"Angiogenesis"},{"issue":"4","key":"5518_CR127","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.cell.2018.01.009","volume":"172","author":"S Su","year":"2018","unstructured":"Su S, et al. CD10\u2009+\u2009GPR77+ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell. 2018;172(4):841\u201356. e16.","journal-title":"Cell"},{"issue":"6","key":"5518_CR128","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"25","author":"AD Rhim","year":"2014","unstructured":"Rhim AD, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25(6):735\u201347.","journal-title":"Cancer Cell"},{"key":"5518_CR129","unstructured":"Bhattacharjee S et al. Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. J Clin Investig, 2024. 131(11)."},{"issue":"17","key":"5518_CR130","doi-asserted-by":"publisher","first-page":"8322","DOI":"10.7150\/thno.62378","volume":"11","author":"Z Li","year":"2021","unstructured":"Li Z, Sun C, Qin Z. Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming. Theranostics. 2021;11(17):8322.","journal-title":"Theranostics"},{"key":"5518_CR131","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ebiom.2018.05.008","volume":"32","author":"A Kock","year":"2018","unstructured":"Kock A, et al. Inhibition of microsomal prostaglandin E synthase-1 in cancer-associated fibroblasts suppresses neuroblastoma tumor growth. EBioMedicine. 2018;32:84\u201392.","journal-title":"EBioMedicine"},{"issue":"7","key":"5518_CR132","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1158\/0008-5472.CAN-21-2116","volume":"82","author":"E Elwakeel","year":"2022","unstructured":"Elwakeel E, et al. Disruption of prostaglandin E2 signaling in cancer-associated fibroblasts limits mammary carcinoma growth but promotes metastasis. Cancer Res. 2022;82(7):1380\u201395.","journal-title":"Cancer Res"},{"key":"5518_CR133","doi-asserted-by":"crossref","unstructured":"Peltier A, et al. Fibroblast heterogeneity in solid tumors: from single cell analysis to whole-body imaging. Seminars in Cancer Biology. Elsevier; 2022.","DOI":"10.1016\/j.semcancer.2022.04.008"},{"issue":"8","key":"5518_CR134","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nri2808","volume":"10","author":"RA Flavell","year":"2010","unstructured":"Flavell RA, et al. The polarization of immune cells in the tumour environment by TGF\u03b2. Nat Rev Immunol. 2010;10(8):554\u201367.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"5518_CR135","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","volume":"16","author":"BA Teicher","year":"2010","unstructured":"Teicher BA, Fricker SP. CXCL12 (SDF-1)\/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16(11):2927\u201331.","journal-title":"Clin Cancer Res"},{"key":"5518_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.591386","volume":"11","author":"S Santagata","year":"2021","unstructured":"Santagata S, et al. CXCR4 and CXCR7 signaling pathways: a focus on the cross-talk between cancer cells and tumor microenvironment. Front Oncol. 2021;11:591386.","journal-title":"Front Oncol"},{"issue":"8","key":"5518_CR137","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1158\/0008-5472.CAN-21-2778","volume":"82","author":"R Wei","year":"2022","unstructured":"Wei R, et al. Ketogenesis attenuates KLF5-dependent production of CXCL12 to overcome the immunosuppressive tumor microenvironment in colorectal cancer. Cancer Res. 2022;82(8):1575\u201388.","journal-title":"Cancer Res"},{"key":"5518_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101809","volume":"83","author":"X Wu","year":"2023","unstructured":"Wu X, et al. CXCL12\/CXCR4: an amazing challenge and opportunity in the fight against fibrosis. Ageing Res Rev. 2023;83:101809.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"5518_CR139","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","volume":"21","author":"D Peng","year":"2022","unstructured":"Peng D, et al. Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022;21(1):104.","journal-title":"Mol Cancer"},{"issue":"7","key":"5518_CR140","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1158\/1541-7786.MCR-17-0784","volume":"16","author":"C Ringuette Goulet","year":"2018","unstructured":"Ringuette Goulet C, et al. Exosomes induce fibroblast differentiation into cancer-associated fibroblasts through TGF\u03b2 signaling. Mol Cancer Res. 2018;16(7):1196\u2013204.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"5518_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00641-0","volume":"6","author":"F Wu","year":"2021","unstructured":"Wu F, et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther. 2021;6(1):218.","journal-title":"Signal Transduct Target Ther"},{"key":"5518_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114527","volume":"188","author":"M Huang","year":"2021","unstructured":"Huang M, et al. TGF-\u03b21-activated cancer-associated fibroblasts promote breast cancer invasion, metastasis and epithelial-mesenchymal transition by autophagy or overexpression of FAP-\u03b1. Biochem Pharmacol. 2021;188:114527.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"5518_CR143","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","volume":"33","author":"A Costa","year":"2018","unstructured":"Costa A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 2018;33(3):463\u201379. e10.","journal-title":"Cancer Cell"},{"issue":"5","key":"5518_CR144","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/cac2.12291","volume":"42","author":"D Hu","year":"2022","unstructured":"Hu D, et al. Cancer-associated fibroblasts in breast cancer: Challenges and opportunities. Cancer Commun. 2022;42(5):401\u201334.","journal-title":"Cancer Commun"},{"key":"5518_CR145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-0972-8","volume":"18","author":"I-H Ham","year":"2019","unstructured":"Ham I-H, et al. Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer. Mol Cancer. 2019;18:1\u201314.","journal-title":"Mol Cancer"},{"key":"5518_CR146","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cytogfr.2022.07.006","volume":"67","author":"X Xiang","year":"2022","unstructured":"Xiang X, et al. Cancer-associated fibroblasts: Vital suppressors of the immune response in the tumor microenvironment. Cytokine Growth Factor Rev. 2022;67:35\u201348.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"8","key":"5518_CR147","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/onc.2016.273","volume":"36","author":"Y Deng","year":"2017","unstructured":"Deng Y, et al. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells. Oncogene. 2017;36(8):1090\u2013101.","journal-title":"Oncogene"},{"issue":"10","key":"5518_CR148","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/s41388-021-02172-y","volume":"41","author":"L Avalle","year":"2022","unstructured":"Avalle L, et al. STAT3 induces breast cancer growth via ANGPTL4, MMP13 and STC1 secretion by cancer associated fibroblasts. Oncogene. 2022;41(10):1456\u201367.","journal-title":"Oncogene"},{"key":"5518_CR149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-020-01258-7","volume":"19","author":"S Zou","year":"2020","unstructured":"Zou S, et al. Targeting STAT3 in cancer immunotherapy. Mol Cancer. 2020;19:1\u201319.","journal-title":"Mol Cancer"},{"issue":"14","key":"5518_CR150","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","volume":"76","author":"X Yang","year":"2016","unstructured":"Yang X, et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3\u2013CCL2 signaling. Cancer Res. 2016;76(14):4124\u201335.","journal-title":"Cancer Res"},{"issue":"19","key":"5518_CR151","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1158\/1078-0432.CCR-18-0205","volume":"24","author":"T Kato","year":"2018","unstructured":"Kato T, et al. Cancer-associated fibroblasts affect intratumoral CD8\u2009+\u2009and FoxP3\u2009+\u2009T cells via IL6 in the tumor microenvironment. Clin Cancer Res. 2018;24(19):4820\u201333.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"5518_CR152","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood B, Najafi M, Mortezaee K. CD8\u2009+\u2009cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234(6):8509\u201321.","journal-title":"J Cell Physiol"},{"issue":"16","key":"5518_CR153","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1158\/0008-5472.CAN-21-4141","volume":"82","author":"L Jenkins","year":"2022","unstructured":"Jenkins L, et al. Cancer-associated fibroblasts suppress CD8\u2009+\u2009T-cell infiltration and confer resistance to immune-checkpoint blockade. Cancer Res. 2022;82(16):2904\u201317.","journal-title":"Cancer Res"},{"issue":"1","key":"5518_CR154","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41467-018-03347-0","volume":"9","author":"MA Lakins","year":"2018","unstructured":"Lakins MA, et al. Cancer-associated fibroblasts induce antigen-specific deletion of CD8\u2009+\u2009T Cells to protect tumour cells. Nat Commun. 2018;9(1):948.","journal-title":"Nat Commun"},{"issue":"1","key":"5518_CR155","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep.32573","volume":"77","author":"H Murai","year":"2023","unstructured":"Murai H, et al. Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma. Hepatology. 2023;77(1):77\u201391.","journal-title":"Hepatology"},{"issue":"6","key":"5518_CR156","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ccell.2022.04.011","volume":"40","author":"H Huang","year":"2022","unstructured":"Huang H, et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell. 2022;40(6):656\u201373. e7.","journal-title":"Cancer Cell"},{"key":"5518_CR157","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1000888","volume":"12","author":"A Burley","year":"2022","unstructured":"Burley A, Rullan A, Wilkins A. A review of the biology and therapeutic implications of cancer-associated fibroblasts (CAFs) in muscle-invasive bladder cancer. Front Oncol. 2022;12:1000888.","journal-title":"Front Oncol"},{"key":"5518_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2020.12.020","volume":"153","author":"J Suzuki","year":"2021","unstructured":"Suzuki J, et al. Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma. Lung Cancer. 2021;153:1\u201310.","journal-title":"Lung Cancer"},{"issue":"14","key":"5518_CR159","doi-asserted-by":"publisher","first-page":"7248","DOI":"10.3390\/ijms22147248","volume":"22","author":"H Gil-Julio","year":"2021","unstructured":"Gil-Julio H, et al. Tumor escape phenotype in bladder cancer is associated with loss of HLA class I expression, T-cell exclusion and stromal changes. Int J Mol Sci. 2021;22(14):7248.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5518_CR160","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/imr.12978","volume":"302","author":"R Mhaidly","year":"2021","unstructured":"Mhaidly R, Mechta-Grigoriou F. Role of cancer\u2010associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer. Immunol Rev. 2021;302(1):259\u201372.","journal-title":"Immunol Rev"},{"issue":"3","key":"5518_CR161","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434\u201352.","journal-title":"Immunity"},{"key":"5518_CR162","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/978-3-319-77736-8_11","volume-title":"The Heterogeneity of Cancer Metabolism","author":"C Sazeides","year":"2018","unstructured":"Sazeides C, Le A. Metabolic relationship between cancer-associated fibroblasts and cancer cells. In: The Heterogeneity of Cancer Metabolism. 2018. p. 149\u201365."},{"key":"5518_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107800","volume":"223","author":"J Li","year":"2021","unstructured":"Li J, et al. Trailblazing perspectives on targeting breast cancer stem cells. Pharmacol Ther. 2021;223:107800.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"5518_CR164","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1053\/j.gastro.2021.08.023","volume":"161","author":"P Nallasamy","year":"2021","unstructured":"Nallasamy P, et al. Pancreatic tumor microenvironment factor promotes cancer stemness via SPP1\u2013CD44 axis. Gastroenterology. 2021;161(6):1998-2013.e7.","journal-title":"Gastroenterology"},{"issue":"1","key":"5518_CR165","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.00018.2019","volume":"100","author":"C Riera-Domingo","year":"2020","unstructured":"Riera-Domingo C, et al. Immunity, hypoxia, and metabolism\u2013the M\u00e9nage \u00e0 Trois of cancer: implications for immunotherapy. Physiol Rev. 2020;100(1):1\u2013102.","journal-title":"Physiol Rev"},{"key":"5518_CR166","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1135456","volume":"13","author":"S Bruni","year":"2023","unstructured":"Bruni S, et al. Cancer immune exclusion: breaking the barricade for a successful immunotherapy. Front Oncol. 2023;13:1135456.","journal-title":"Front Oncol"},{"issue":"1","key":"5518_CR167","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.12766","volume":"290","author":"BA Wilky","year":"2019","unstructured":"Wilky BA. Immune checkpoint inhibitors: The linchpins of modern immunotherapy. Immunol Rev. 2019;290(1):6\u201323.","journal-title":"Immunol Rev"},{"issue":"4","key":"5518_CR168","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/cells14040283","volume":"14","author":"B Arneth","year":"2025","unstructured":"Arneth B. Molecular Mechanisms of Immune Regulation: A Review. Cells. 2025;14(4):283.","journal-title":"Cells"},{"key":"5518_CR169","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231186027","volume":"15","author":"FY Kreidieh","year":"2023","unstructured":"Kreidieh FY, Tawbi HA. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition. Ther Adv Med Oncol. 2023;15:17588359231186027.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"5518_CR170","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","volume":"23","author":"HE Marei","year":"2023","unstructured":"Marei HE, et al. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int. 2023;23(1):64.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"5518_CR171","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.clgc.2023.01.005","volume":"21","author":"FSM Monteiro","year":"2023","unstructured":"Monteiro FSM, et al. The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): a systematic review and meta-analysis. Clin Genitourin Cancer. 2023;21(3):324\u201333.","journal-title":"Clin Genitourin Cancer"},{"key":"5518_CR172","doi-asserted-by":"publisher","first-page":"101636","DOI":"10.1016\/j.tranon.2023.101636","volume":"30","author":"Z Davoodi-Moghaddam","year":"2023","unstructured":"Davoodi-Moghaddam Z, et al. A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe? Translational Oncol. 2023;30:101636.","journal-title":"Translational Oncol"},{"issue":"10","key":"5518_CR173","doi-asserted-by":"publisher","first-page":"354","DOI":"10.21037\/atm-22-4218","volume":"11","author":"A Olivares-Hern\u00e1ndez","year":"2023","unstructured":"Olivares-Hern\u00e1ndez A, et al. Immune checkpoint inhibitors in non-small cell lung cancer: From current perspectives to future treatments\u2014A systematic review. Annals Translational Med. 2023;11(10):354.","journal-title":"Annals Translational Med"},{"issue":"5","key":"5518_CR174","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.clgc.2022.04.008","volume":"20","author":"FSM Monteiro","year":"2022","unstructured":"Monteiro FSM, et al. A systematic review and meta-analysis of the role of immune checkpoint inhibitors (ICI) as adjuvant treatment for localized high-risk muscle-invasive urothelial carcinoma (MIUC). Clin Genitourin Cancer. 2022;20(5):391\u20138.","journal-title":"Clin Genitourin Cancer"},{"key":"5518_CR175","doi-asserted-by":"crossref","unstructured":"Rodriguez MA et al. Mechanism of Action and Pharmacologic Features of Drugs Targeting PD-1\/PDL-1 and CTLA-4. Precision Cancer Therapies vol 2\u2010Immunologic Approaches for the Treatment of Lymphoid Malignancies\u2010From Concept to Practice, 2024: pp. 139\u2013155.","DOI":"10.1002\/9781119824572.ch11"},{"key":"5518_CR176","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.651634","volume":"12","author":"M Khan","year":"2021","unstructured":"Khan M, Arooj S, Wang H. Soluble B7-CD28 family inhibitory immune checkpoint proteins and anti-cancer immunotherapy. Front Immunol. 2021;12:651634.","journal-title":"Front Immunol"},{"issue":"6","key":"5518_CR177","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1200\/JCO.21.01845","volume":"40","author":"A Passaro","year":"2022","unstructured":"Passaro A, et al. Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies. J Clin Oncol. 2022;40(6):598\u2013610.","journal-title":"J Clin Oncol"},{"key":"5518_CR178","unstructured":"Poorkhani A, et al. Emerging new immune checkpoint inhibitors in solid tumor immunotherapy. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology; 2025. pp. 1\u201328."},{"issue":"3","key":"5518_CR179","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.7150\/ijbs.104079","volume":"21","author":"Q Liu","year":"2025","unstructured":"Liu Q, et al. Revisiting of Cancer Immunotherapy: Insight from the Dialogue between Glycolysis and PD-1\/PD-L1 Axis in the Tumor Microenvironment. Int J Biol Sci. 2025;21(3):1202.","journal-title":"Int J Biol Sci"},{"issue":"8","key":"5518_CR180","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41571-025-01035-9","volume":"22","author":"S Zhao","year":"2025","unstructured":"Zhao S, et al. The next generation of immunotherapies for lung cancers. Nat reviews Clin Oncol. 2025;22(8):592\u2013616.","journal-title":"Nat reviews Clin Oncol"},{"issue":"6","key":"5518_CR181","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","volume":"24","author":"LH Butterfield","year":"2024","unstructured":"Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2024;24(6):399\u2013416.","journal-title":"Nat Rev Immunol"},{"key":"5518_CR182","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-021-02407-8","volume":"22","author":"S Vafaei","year":"2022","unstructured":"Vafaei S, et al. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int. 2022;22:1\u201327.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"5518_CR183","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3390\/cancers13040678","volume":"13","author":"A Procureur","year":"2021","unstructured":"Procureur A, et al. Enhance the immune checkpoint inhibitors efficacy with radiotherapy induced immunogenic cell death: A comprehensive review and latest developments. Cancers. 2021;13(4):678.","journal-title":"Cancers"},{"issue":"1","key":"5518_CR184","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","volume":"7","author":"Y Tian","year":"2022","unstructured":"Tian Y, Xie D, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct Target therapy. 2022;7(1):117.","journal-title":"Signal Transduct Target therapy"},{"issue":"1","key":"5518_CR185","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12943-023-01800-3","volume":"22","author":"X Chu","year":"2023","unstructured":"Chu X, et al. Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials. Mol Cancer. 2023;22(1):93.","journal-title":"Mol Cancer"},{"key":"5518_CR186","doi-asserted-by":"publisher","DOI":"10.5603\/ocp.102398","author":"N Krzy\u017canowska","year":"2025","unstructured":"Krzy\u017canowska N. T cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte-activation gene 3 (LAG-3), and T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT)\u2014an update on emerging negative immune checkpoints in cancer treatment. Oncol Clin Pract. 2025. https:\/\/doi.org\/10.5603\/ocp.102398.","journal-title":"Oncol Clin Pract"},{"key":"5518_CR187","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1568664","volume":"16","author":"K Ghasemi","year":"2025","unstructured":"Ghasemi K. Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy. Front Pharmacol. 2025;16:1568664.","journal-title":"Front Pharmacol"},{"key":"5518_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21776","author":"C Wang","year":"2023","unstructured":"Wang C, et al. CAR-T cell therapy for hematological malignancies: history, status and promise. Heliyon. 2023. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e21776.","journal-title":"Heliyon"},{"issue":"1","key":"5518_CR189","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00373-7","volume":"12","author":"T Yan","year":"2023","unstructured":"Yan T, Zhu L, Chen J. Current advances and challenges in CAR T-cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. 2023;12(1):14.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"5518_CR190","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41417-021-00307-7","volume":"28","author":"M Poorebrahim","year":"2021","unstructured":"Poorebrahim M, et al. TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential. Cancer Gene Ther. 2021;28(6):581\u20139.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"5518_CR191","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00018-021-04089-x","volume":"79","author":"Y Duan","year":"2022","unstructured":"Duan Y, et al. Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy. Cell Mol Life Sci. 2022;79(1):14.","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"5518_CR192","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3390\/ijms22042150","volume":"22","author":"M Martino","year":"2021","unstructured":"Martino M, et al. A review of clinical outcomes of CAR T-cell therapies for B-acute lymphoblastic leukemia. Int J Mol Sci. 2021;22(4):2150.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"5518_CR193","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29123","volume":"68","author":"SJ Si Lim","year":"2021","unstructured":"Si Lim SJ, Grupp SA, DiNofia AM. Tisagenlecleucel for treatment of children and young adults with relapsed\/refractory B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021;68(9):e29123.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"5518_CR194","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1177\/1060028020948165","volume":"55","author":"Z Halford","year":"2021","unstructured":"Halford Z, et al. Tisagenlecleucel in acute lymphoblastic leukemia: a review of the literature and practical considerations. Ann Pharmacother. 2021;55(4):466\u201379.","journal-title":"Ann Pharmacother"},{"key":"5518_CR195","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1305657","volume":"11","author":"S Negishi","year":"2024","unstructured":"Negishi S, et al. Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma. Front Pediatr. 2024;11:1305657.","journal-title":"Front Pediatr"},{"key":"5518_CR196","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02148-6","author":"X Xiao","year":"2021","unstructured":"Xiao X, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021. https:\/\/doi.org\/10.1186\/s13046-021-02148-6.","journal-title":"J Exp Clin Cancer Res"},{"key":"5518_CR197","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jha2.356","volume":"3","author":"U Patel","year":"2022","unstructured":"Patel U, et al. CAR T cell therapy in solid tumors: A review of current clinical trials. EJHaem. 2022;3:24\u201331.","journal-title":"EJHaem"},{"key":"5518_CR198","doi-asserted-by":"publisher","first-page":"1113882","DOI":"10.3389\/fimmu.2023.1113882","volume":"14","author":"A Daei Sorkhabi","year":"2023","unstructured":"Daei Sorkhabi A, et al. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. Front Immunol. 2023;14:1113882.","journal-title":"Front Immunol"},{"issue":"1","key":"5518_CR199","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12943-024-02079-8","volume":"23","author":"X Xia","year":"2024","unstructured":"Xia X, et al. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy. Mol Cancer. 2024;23(1):175.","journal-title":"Mol Cancer"},{"key":"5518_CR200","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117252","volume":"178","author":"H Lin","year":"2024","unstructured":"Lin H, et al. Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies. Biomed Pharmacother. 2024;178:117252.","journal-title":"Biomed Pharmacother"},{"key":"5518_CR201","doi-asserted-by":"crossref","unstructured":"Mangolini M et al. Highly potent novel multi-armoured IL13R\u03b12 CAR-T subverts the immunosuppressive microenvironment of Glioblastoma. bioRxiv, 2025: p. 2025.01. 10.632392","DOI":"10.1101\/2025.01.10.632392"},{"issue":"1","key":"5518_CR202","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1038\/s41467-024-49034-1","volume":"15","author":"Z Zou","year":"2024","unstructured":"Zou Z, et al. Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8\u2009+\u2009T cells for systemic antitumor responses. Nat Commun. 2024;15(1):4701.","journal-title":"Nat Commun"},{"issue":"1","key":"5518_CR203","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41571-024-00959-y","volume":"22","author":"C Diorio","year":"2025","unstructured":"Diorio C, Teachey DT, Grupp SA. Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks. Nat Reviews Clin Oncol. 2025;22(1):10\u201327.","journal-title":"Nat Reviews Clin Oncol"},{"key":"5518_CR204","doi-asserted-by":"crossref","unstructured":"Bot A et al. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat Rev Drug Discovery, 2025: pp. 1\u201322.","DOI":"10.69645\/NEPO7828"},{"issue":"5","key":"5518_CR205","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2174\/0115748928277331231218115402","volume":"19","author":"Y Liu","year":"2024","unstructured":"Liu Y, et al. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies. Recent Pat Anti-cancer Drug Discov. 2024;19(5):557\u201372.","journal-title":"Recent Pat Anti-cancer Drug Discov"},{"key":"5518_CR206","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1679092","volume":"16","author":"JA Lopatnikova","year":"2025","unstructured":"Lopatnikova JA, Sennikov SV. Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives. Front Immunol. 2025;16:1679092.","journal-title":"Front Immunol"},{"issue":"2","key":"5518_CR207","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1039\/D1CB00082A","volume":"3","author":"F Thoreau","year":"2022","unstructured":"Thoreau F, Chudasama V. Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry. RSC Chem Biology. 2022;3(2):140\u201369.","journal-title":"RSC Chem Biology"},{"issue":"2","key":"5518_CR208","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.htct.2023.06.006","volume":"46","author":"R Mirfakhraie","year":"2024","unstructured":"Mirfakhraie R, et al. All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia. Hematol Transfus Cell Ther. 2024;46(2):192\u2013200.","journal-title":"Hematol Transfus Cell Ther"},{"issue":"7","key":"5518_CR209","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","volume":"21","author":"M-E Goebeler","year":"2024","unstructured":"Goebeler M-E, Stuhler G, Bargou R. Bispecific and multispecific antibodies in oncology: opportunities and challenges. Nat Reviews Clin Oncol. 2024;21(7):539\u201360.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"1","key":"5518_CR210","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40259-024-00691-0","volume":"39","author":"DA Ellerman","year":"2025","unstructured":"Ellerman DA. The evolving applications of bispecific antibodies: reaping the harvest of early sowing and planting new seeds. BioDrugs. 2025;39(1):75\u2013102.","journal-title":"BioDrugs"},{"issue":"2","key":"5518_CR211","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/0115748863286774240219094217","volume":"20","author":"B Khushboo","year":"2025","unstructured":"Khushboo B, Kumar JR. Perils and problems in bispecific T-cell engager antibodies. Curr Drug Saf. 2025;20(2):85\u20138.","journal-title":"Curr Drug Saf"},{"issue":"2","key":"5518_CR212","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/cancers13020287","volume":"13","author":"J Middelburg","year":"2021","unstructured":"Middelburg J, et al. Overcoming challenges for CD3-bispecific antibody therapy in solid tumors. Cancers. 2021;13(2):287.","journal-title":"Cancers"},{"key":"5518_CR213","doi-asserted-by":"crossref","unstructured":"Bergamaschi C, et al. Innovative strategies for T cell engagers for cancer immunotherapy. MAbs. Taylor & Francis; 2025.","DOI":"10.1080\/19420862.2025.2531223"},{"issue":"3","key":"5518_CR214","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473148","volume":"45","author":"L Guidi","year":"2025","unstructured":"Guidi L, et al. Bispecific antibodies in hematologic and solid tumors: current landscape and therapeutic advances. Am Soc Clin Oncol Educ Book. 2025;45(3):e473148.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"5518_CR215","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.06.003","author":"A Brandenburg","year":"2024","unstructured":"Brandenburg A, Heine A, Brossart P. Next-generation cancer vaccines and emerging immunotherapy combinations. Trends Cancer. 2024. https:\/\/doi.org\/10.1016\/j.trecan.2024.06.003.","journal-title":"Trends Cancer"},{"issue":"2","key":"5518_CR216","doi-asserted-by":"publisher","first-page":"352","DOI":"10.20892\/j.issn.2095-3941.2021.0004","volume":"18","author":"J Liang","year":"2021","unstructured":"Liang J, Zhao X. Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development. Cancer Biol Med. 2021;18(2):352\u201371.","journal-title":"Cancer Biol Med"},{"key":"5518_CR217","unstructured":"Khanmiri JM et al. Dendritic cell vaccination strategy for the treatment of acute myeloid leukemia: a systematic review. Cytotherapy, 2024."},{"issue":"5","key":"5518_CR218","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jcyt.2024.02.009","volume":"26","author":"JM Khanmiri","year":"2024","unstructured":"Khanmiri JM, et al. Dendritic cell vaccination strategy for the treatment of acute myeloid leukemia: a systematic review. Cytotherapy. 2024;26(5):427\u201335.","journal-title":"Cytotherapy"},{"key":"5518_CR219","doi-asserted-by":"publisher","DOI":"10.37349\/ei.2025.1003190","volume":"5","author":"AA Aljabali","year":"2025","unstructured":"Aljabali AA, et al. Neoantigen vaccines: advancing personalized cancer immunotherapy. Exploration of Immunology. 2025;5:1003190.","journal-title":"Exploration of Immunology"},{"issue":"1","key":"5518_CR220","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target therapy. 2023;8(1):156.","journal-title":"Signal Transduct Target therapy"},{"key":"5518_CR221","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1038226","volume":"13","author":"L Palanivelu","year":"2023","unstructured":"Palanivelu L, Liu C-H, Lin L-T. Immunogenic cell death: the cornerstone of oncolytic viro-immunotherapy. Front Immunol. 2023;13:1038226.","journal-title":"Front Immunol"},{"issue":"8","key":"5518_CR222","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1111\/cas.15450","volume":"113","author":"N Yamazaki","year":"2022","unstructured":"Yamazaki N, et al. A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma. Cancer Sci. 2022;113(8):2798\u2013806.","journal-title":"Cancer Sci"},{"issue":"3","key":"5518_CR223","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"SZ Shalhout","year":"2023","unstructured":"Shalhout SZ, et al. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20(3):160\u201377.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"5518_CR224","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1158\/2159-8290.CD-19-0790","volume":"10","author":"AJ Anandappa","year":"2020","unstructured":"Anandappa AJ, Wu CJ, Ott PA. Directing traffic: how to effectively drive T cells into tumors. Cancer Discov. 2020;10(2):185\u201397.","journal-title":"Cancer Discov"},{"key":"5518_CR225","unstructured":"Quixabeira DC. Facilitating cancer immunotherapies with armed oncolytic adenoviruses. 2023."},{"key":"5518_CR226","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.844142","volume":"13","author":"B Lv","year":"2022","unstructured":"Lv B, et al. Immunotherapy: reshape the tumor immune microenvironment. Front Immunol. 2022;13:844142.","journal-title":"Front Immunol"},{"key":"5518_CR227","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.882718","volume":"13","author":"S-J Kim","year":"2022","unstructured":"Kim S-J, Khadka D, Seo JH. Interplay between solid tumors and tumor microenvironment. Front Immunol. 2022;13:882718.","journal-title":"Front Immunol"},{"issue":"9","key":"5518_CR228","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.200111","volume":"10","author":"MM Yaseen","year":"2020","unstructured":"Yaseen MM, et al. Mechanisms of immune suppression by myeloid-derived suppressor cells: the role of interleukin-10 as a key immunoregulatory cytokine. Open Biol. 2020;10(9):200111.","journal-title":"Open Biol"},{"issue":"12","key":"5518_CR229","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123802","volume":"12","author":"RC Augustin","year":"2020","unstructured":"Augustin RC, Delgoffe GM, Najjar YG. Characteristics of the tumor microenvironment that influence immune cell functions: hypoxia, oxidative stress, metabolic alterations. Cancers (Basel). 2020;12(12):3802.","journal-title":"Cancers (Basel)"},{"key":"5518_CR230","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954992","volume":"13","author":"MT Bilotta","year":"2022","unstructured":"Bilotta MT, Antignani A, Fitzgerald DJ. Managing the TME to improve the efficacy of cancer therapy. Front Immunol. 2022;13:954992.","journal-title":"Front Immunol"},{"issue":"10","key":"5518_CR231","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.3390\/biomedicines12102381","volume":"12","author":"C Tomassetti","year":"2024","unstructured":"Tomassetti C, et al. Insights into CSF-1R expression in the tumor microenvironment. Biomedicines. 2024;12(10):2381.","journal-title":"Biomedicines"},{"issue":"11","key":"5518_CR232","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112895","volume":"15","author":"TW Stone","year":"2023","unstructured":"Stone TW, Williams RO. Interactions of IDO and the kynurenine pathway with cell transduction systems and metabolism at the inflammation\u2013cancer interface. Cancers (Basel). 2023;15(11):2895.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"5518_CR233","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202403019R","volume":"39","author":"P Liang","year":"2025","unstructured":"Liang P, et al. Metabolic reprogramming of glycolysis, lipids, and amino acids in tumors: impact on CD8+ T cell function and targeted therapeutic strategies. FASEB J. 2025;39(8):e70520.","journal-title":"FASEB J"},{"issue":"4","key":"5518_CR234","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41571-025-01000-6","volume":"22","author":"SW Linderman","year":"2025","unstructured":"Linderman SW, et al. Enhancing immunotherapy with tumour-responsive nanomaterials. Nat Reviews Clin Oncol. 2025;22(4):262\u201382.","journal-title":"Nat Reviews Clin Oncol"},{"key":"5518_CR235","first-page":"300","volume":"17","author":"S Han","year":"2022","unstructured":"Han S, Wu J. Three-dimensional (3D) scaffolds as powerful weapons for tumor immunotherapy. Bioact Mater. 2022;17:300\u201319.","journal-title":"Bioact Mater"},{"issue":"4","key":"5518_CR236","doi-asserted-by":"publisher","first-page":"248","DOI":"10.20892\/j.issn.2095-3941.2023.0009","volume":"20","author":"W Yi","year":"2023","unstructured":"Yi W, et al. Smart drug delivery systems to overcome drug resistance in cancer immunotherapy. Cancer Biol Med. 2023;20(4):248\u201367.","journal-title":"Cancer Biol Med"},{"issue":"11","key":"5518_CR237","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/thno.58390","volume":"11","author":"Y-T Liu","year":"2021","unstructured":"Liu Y-T, Sun Z-J. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11(11):5365.","journal-title":"Theranostics"},{"issue":"3","key":"5518_CR238","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2217\/imt.15.126","volume":"8","author":"T Hato","year":"2016","unstructured":"Hato T, Zhu AX, Duda DG. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy. 2016;8(3):299\u2013313.","journal-title":"Immunotherapy"},{"key":"5518_CR239","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107441","volume":"187","author":"C Gridelli","year":"2024","unstructured":"Gridelli C, et al. Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: results of an international expert panel meeting by the Italian association of thoracic oncology (AIOT). Lung Cancer. 2024;187:107441.","journal-title":"Lung Cancer"},{"issue":"4","key":"5518_CR240","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/CMR.0000000000000669","volume":"30","author":"JV Aguilera","year":"2020","unstructured":"Aguilera JV, et al. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Res. 2020;30(4):364\u201375.","journal-title":"Melanoma Res"},{"issue":"1","key":"5518_CR241","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3892\/ol.2025.15088","volume":"30","author":"C Ma","year":"2025","unstructured":"Ma C, et al. Combination of radiotherapy and ICIs in advanced hepatocellular carcinoma: A systematic review of current evidence and future prospects. Oncol Lett. 2025;30(1):342.","journal-title":"Oncol Lett"},{"issue":"1","key":"5518_CR242","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00432-019-03094-9","volume":"146","author":"W Li","year":"2020","unstructured":"Li W, Yu H. Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases. J Cancer Res Clin Oncol. 2020;146(1):137\u201352.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"5518_CR243","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70112","volume":"16","author":"J Xu","year":"2025","unstructured":"Xu J, et al. The efficacy and safety of brain radiotherapy combined with immune checkpoint inhibitors (ICIs) for small-cell lung cancer (SCLC) patients with brain metastases (BMs). Thorac Cancer. 2025;16(12):e70112.","journal-title":"Thorac Cancer"},{"issue":"24","key":"5518_CR244","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.2217\/fon-2022-0440","volume":"18","author":"UM Lauer","year":"2022","unstructured":"Lauer UM, Beil J. Oncolytic viruses: challenges and considerations in an evolving clinical landscape. Future Oncol. 2022;18(24):2713\u201332.","journal-title":"Future Oncol"},{"key":"5518_CR245","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.trsl.2021.04.008","volume":"237","author":"N Abd-Aziz","year":"2021","unstructured":"Abd-Aziz N, Poh CL. Development of oncolytic viruses for cancer therapy. Translational Res. 2021;237:98\u2013123.","journal-title":"Translational Res"},{"key":"5518_CR246","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S494670","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, et al. Immune checkpoint inhibitor combined with antiangiogenic agent synergistically improving the treatment efficacy for solid tumors. ImmunoTargets Ther. 2024. https:\/\/doi.org\/10.2147\/ITT.S494670.","journal-title":"ImmunoTargets Ther"},{"issue":"9","key":"5518_CR247","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41571-024-00926-7","volume":"21","author":"J Chen","year":"2024","unstructured":"Chen J, et al. Spatial landscapes of cancers: insights and opportunities. Nat reviews Clin Oncol. 2024;21(9):660\u201374.","journal-title":"Nat reviews Clin Oncol"},{"issue":"7","key":"5518_CR248","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41416-021-01413-x","volume":"125","author":"C Pilard","year":"2021","unstructured":"Pilard C, et al. Cancer immunotherapy: it\u2019s time to better predict patients\u2019 response. Br J Cancer. 2021;125(7):927\u201338.","journal-title":"Br J Cancer"},{"issue":"3","key":"5518_CR249","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41591-024-02823-z","volume":"30","author":"A Gunjur","year":"2024","unstructured":"Gunjur A, et al. A gut microbial signature for combination immune checkpoint blockade across cancer types. Nat Med. 2024;30(3):797\u2013809.","journal-title":"Nat Med"},{"key":"5518_CR250","unstructured":"Duttagupta S et al. Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial. Nat Med, 2026: pp. 1\u201314."},{"issue":"4","key":"5518_CR251","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.immuni.2018.03.018","volume":"48","author":"J Li","year":"2018","unstructured":"Li J, et al. Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8\u2009+\u2009T cells. Immunity. 2018;48(4):773\u201386. e5.","journal-title":"Immunity"},{"issue":"25","key":"5518_CR252","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500\u20131.","journal-title":"N Engl J Med"},{"issue":"6349","key":"5518_CR253","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313.","journal-title":"Science"},{"key":"5518_CR254","unstructured":"Li F et al. The Association between Cd8\u2009+\u2009tumor-infiltrating lymphocytes and response to cancer immunotherapy: a systematic review and meta-analysis. Available at SSRN 3868057."},{"issue":"1","key":"5518_CR255","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41392-024-01988-w","volume":"9","author":"S-W Huang","year":"2024","unstructured":"Huang S-W, et al. Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials. Signal Transduct Target Therapy. 2024;9(1):285.","journal-title":"Signal Transduct Target Therapy"},{"issue":"3","key":"5518_CR256","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00262-021-03018-y","volume":"71","author":"DH Kang","year":"2022","unstructured":"Kang DH, et al. Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1\/PD-L1 inhibitors. Cancer Immunol Immunother. 2022;71(3):579\u201388.","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"5518_CR257","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1007\/s00262-021-02898-4","volume":"70","author":"B Han","year":"2021","unstructured":"Han B, et al. The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte. Cancer Immunol Immunother. 2021;70(10):2893\u2013909.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"5518_CR258","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1007\/s00262-023-03464-w","volume":"72","author":"H Himuro","year":"2023","unstructured":"Himuro H, et al. Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors. Cancer Immunol Immunother. 2023;72(8):2829\u201340.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"5518_CR259","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/cancers13010097","volume":"13","author":"A Costantini","year":"2020","unstructured":"Costantini A, et al. Plasma biomarkers screening by multiplex ELISA assay in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Cancers. 2020;13(1):97.","journal-title":"Cancers"},{"issue":"1","key":"5518_CR260","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17592-3","volume":"12","author":"MH Lee","year":"2022","unstructured":"Lee MH, et al. The tumor and plasma cytokine profiles of renal cell carcinoma patients. Sci Rep. 2022;12(1):13416.","journal-title":"Sci Rep"},{"issue":"3","key":"5518_CR261","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s12325-020-01229-w","volume":"37","author":"A Russo","year":"2020","unstructured":"Russo A, et al. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with nivolumab in pretreated non-small cell lung cancer (NSCLC): a large retrospective multicenter study. Adv Ther. 2020;37(3):1145\u201355.","journal-title":"Adv Ther"},{"key":"5518_CR262","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1205897","volume":"10","author":"Q Chen","year":"2023","unstructured":"Chen Q, et al. The neutrophil-to-lymphocyte ratio and lactate dehydrogenase combined in predicting liver metastasis and prognosis of colorectal cancer. Front Med. 2023;10:1205897.","journal-title":"Front Med"},{"issue":"1","key":"5518_CR263","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13568-022-01428-4","volume":"12","author":"A Grenda","year":"2022","unstructured":"Grenda A, et al. Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer. AMB Express. 2022;12(1):86.","journal-title":"AMB Express"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05518-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05518-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05518-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:02:15Z","timestamp":1790301735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05518-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":263,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5518"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05518-8","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This review article does not involve studies with human participants or animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form (including individual details, images, or videos), and no specific consent was required.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1375"}}